Drugs known as GLP-1 receptor agonists were initially developed to treat Type 2 diabetes but have become a cultural ...

Trump is changing Medicare, mostly focusing on providers. But the biggest impact may come from tariffs and deporting ...

The Trump administration is planning an experiment to cover weight-loss drugs under Medicare and Medicaid, the Washington ...

President Donald Trump is ratcheting up the pressure on major drugmakers to bring their US prices in line with the far lower ...

Proposed experiment would allow states and Medicare drug plans to cover GLP-1 drugs like Ozempic and Wegovy for obesity, The ...

In letters posted on Truth Social, Trump demanded that drugmakers offer their medications at the same prices paid abroad.

The Washington Post reported the CMS is considering a plan that could allow Medicare plans to pay for the drugs.

The drugs reportedly under consideration for coverage include Novo Nordisk's Wegovy and Ozempic, and Eli Lilly's Zepbound and ...

The Trump administration is exploring a five-year pilot program to include weight-loss drugs like Wegovy, Ozempic, Zepbound, ...

President Donald Trump has sent letters to pharmaceutical companies, aiming to compel them to lower drug prices in the US to ...

The administration is working with tech companies to make sharing information with various providers easier. Experts raised ...

Several companies, including Oracle and Microsoft, are expected to sign pledges to work on the Trump administration ...